Search
Filter by content type
Filter by content year
Filter by category
BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165
December 23, 2022 - … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit …
BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo® (cemiplimab) Combination in NSCLC
March 8, 2022 - … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer. For more information, please visit … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer. For more information, please visit … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer. For more information, please visit …
BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163
December 21, 2022 - … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit …
BioNTech Announces Plans for a Clinical Trial hub in Taiwan for mRNA-based Cancer Immunotherapies as Part of Asia-Pacific Expansion
December 16, 2022 - … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit …
BioNTech Presents Positive Preliminary Phase 1/2 Data for First-in-Class CAR-T Program BNT211 at AACR
April 11, 2022 - … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer. For more information, please visit … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer. For more information, please visit … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer. For more information, please visit …
BioNTech Presents Encouraging Phase 1/2 Follow-up Data for CAR-T Candidate BNT211 in Hard-To-Treat Solid Tumors at ESMO
September 9, 2022 - … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit …
Positive Phase 1 Data from mRNA-based Individualized Neoantigen Specific Immunotherapy in Patients with Resected Pancreatic Cancer presented at ASCO
June 5, 2022 - … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer. For more information, please visit … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer. For more information, please visit … a member of the Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer. For more information, please visit …
BioNTech beginnt klinische Phase-1-Studie mit Malaria-Impfstoffprogramm BNT165
December 23, 2022 - … (ein Unternehmen der Roche Gruppe), Regeneron, Genevant, Fosun Pharma und Pfizer. Weitere Information finden Sie … (ein Unternehmen der Roche Gruppe), Regeneron, Genevant, Fosun Pharma und Pfizer. Weitere Information finden Sie … (ein Unternehmen der Roche Gruppe), Regeneron, Genevant, Fosun Pharma und Pfizer. Weitere Information finden Sie …
BioNTech und Regeneron erweitern strategische Zusammenarbeit zur klinischen Entwicklung von FixVac und Libtayo® (Cemiplimab) Kombination gegen nicht-kleinzelliges Lungenkarzinom
March 8, 2022 - … (ein Unternehmen der Roche Gruppe), Regeneron, Genevant, Fosun Pharma und Pfizer. Weitere Information finden Sie … (ein Unternehmen der Roche Gruppe), Regeneron, Genevant, Fosun Pharma und Pfizer. Weitere Information finden Sie … (ein Unternehmen der Roche Gruppe), Regeneron, Genevant, Fosun Pharma und Pfizer. Weitere Information finden Sie …
BioNTech beginnt Phase-1-Studie mit prophylaktischem Impfstoffkandidaten BNT163 gegen Herpes-Simplex-Virus-2
December 21, 2022 - … (ein Unternehmen der Roche Gruppe), Regeneron, Genevant, Fosun Pharma und Pfizer. Weitere Information finden Sie … (ein Unternehmen der Roche Gruppe), Regeneron, Genevant, Fosun Pharma und Pfizer. Weitere Information finden Sie … (ein Unternehmen der Roche Gruppe), Regeneron, Genevant, Fosun Pharma und Pfizer. Weitere Information finden Sie …